Frequent mutations in SH2D1A (XLP) in males presenting with high-grade mature B-cell neoplasms

Pediatric Blood and Cancer

Volumn 60, Issue 9, 2013, Pages

  Sandlund, J T ^a,b   Shurtleff, S A ^a   Onciu, M ^a,b   Horwitz, E ^a,c   Leung, W ^a,b   Howard, V ^a   Rencher, R ^a   Conley, M E ^a,b  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF TENNESSEE COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

B cells; EBV; Lymphoma; XLP

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPSTEIN BARR VIRUS ANTIGEN 1; MERCAPTOPURINE; METHOTREXATE; PREDNISONE; RITUXIMAB; SIGNALING LYMPHOCYTE ACTIVATION MOLECULE ASSOCIATED PROTEIN; VINCRISTINE;

ARTICLE; BURKITT LYMPHOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER REGISTRY; EXON; GENE MUTATION; GENETIC SCREENING; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNOPHENOTYPING; LARGE CELL LYMPHOMA; LIVER FAILURE; LYMPHOPROLIFERATIVE DISEASE; MAJOR CLINICAL STUDY; MALE; MONONUCLEOSIS; MULTIMODALITY CANCER THERAPY; NUCLEOTIDE SEQUENCE; PNEUMONIA; PRIORITY JOURNAL; RESPIRATORY FAILURE; RETROSPECTIVE STUDY; X LINKED LYMPHOPROLIFERATIVE DISEASE;

B CELLS; EBV; LYMPHOMA; XLP;

FOLLOW-UP STUDIES; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LYMPHOMA, LARGE B-CELL, DIFFUSE; LYMPHOPROLIFERATIVE DISORDERS; MALE; MUTATION; REGISTRIES; RETROSPECTIVE STUDIES;

EID: 84880326475     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.24525     Document Type: Article

References (20)

1. Purtilo DT, DeFlorio D, Jr., Hutt LM, et al. Variable phenotypic expression of an X-linked recessive lymphoproliferative syndrome. N Engl J Med 1977; 297:1077-1080.
2. Purtilo DT, Cassel CK, Yang JP, et al. X-linked recessive progressive combined variable immunodeficiency (Duncan's disease). Lancet 1975; 1:935-940.
3. Nichols KE, Ma CS, Cannons JL, et al. Molecular and cellular pathogenesis of X-linked lymphoproliferative disease. Immunol Rev 2005; 203:180-199.
4. Filipovich A, Conley ME, Nichols KE, et al. X-linked lymphoproliferative syndrome: An X-cellent question. Clin Immunol 2006; 119:241-244.
5. Filipovich AH, Zhang K, Snow AL, et al. X-linked lymphoproliferative syndromes: Brothers or distant cousins? Blood 2010; 116:3398-3408.
6. Morra M, Silander O, Calpe S, et al. Alterations of the X-linked lymphoproliferative disease gene SH2D1A in common variable immunodeficiency syndrome. Blood 2001; 98:1321-1325.
7. Seemayer TA, Gross TG, Egeler RM, et al. X-linked lymphoproliferative disease: Twenty-five years after the discovery. Pediatr Res 1995; 38:471-478.
8. Sumegi J, Huang D, Lanyi A, et al. Correlation of mutations of the SH2D1A gene and Epstein-Barr virus infection with clinical phenotype and outcome in X-linked lymphoproliferative disease. Blood 2000; 96:3118-3125.
9. Brandau O, Schuster V, Weiss M, et al. Epstein-Barr virus-negative boys with non-Hodgkin lymphoma are mutated in the SH2D1A gene, as are patients with X-linked lymphoproliferative disease (XLP). Hum Mol Genet 1999; 8:2407-2413.
10. Parolini O, Kagerbauer B, Simonitsch-Klupp I, et al. Analysis of SH2D1A mutations in patients with severe Epstein-Barr virus infections, Burkitt's lymphoma, and Hodgkin's lymphoma. Ann Hematol 2002; 81:441-447.
11. Purtilo DT, Yasuda N, Grierson HL, et al. X-linked lymphoproliferative syndrome provides clues to the pathogenesis of Epstein-Barr virus-induced lymphomagenesis. Princess Takamatsu Symp 1987; 18:149-158.
12. Yin LTT, Pauly S, Lenoir G, et al. Absence of mutation in 62 Burkitt lymphoma cell lines. Am J Hum Genet 1999; 65:A1868.
13. Jaffe ES, Harris NL, Stein H, et al. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC Press; 2001.
14. Swerdlow SHCE, Harris NL, Jaffe ES, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC Press; 2008.
15. Williams LL, Rooney CM, Conley ME, et al. Correction of Duncan's syndrome by allogeneic bone marrow transplantation. Lancet 1993; 342:587-588.
16. Nichols KE, Harkin DP, Levitz S, et al. Inactivating mutations in an SH2 domain-encoding gene in X-linked lymphoproliferative syndrome. Proc Natl Acad Sci USA 1998; 95:13765-13770.
17. Murphy SB. Classification, staging and end results of treatment of childhood non-Hodgkin's lymphomas: Dissimilarities from lymphomas in adults. Sem Oncol 1980; 7:332-339.
18. Murphy SB, Bowman WP, Abromowitch M, et al. Results of treatment of advanced-stage Burkitt's lymphoma and B cell (SIg+) acute lymphoblastic leukemia with high-dose fractionated cyclophosphamide and coordinated high-dose methotrexate and cytarabine. J Clin Oncol 1986; 4:1732-1739.
19. Patte C, Auperin A, Gerrard M, et al. Results of the randomized international FAB/LMB96 trial for intermediate risk B-cell non-Hodgkin lymphoma in children and adolescents: It is possible to reduce treatment for the early responding patients. Blood 2007; 109:2773-2780.
20. Patte C, Auperin A, Michon J, et al. The Societe Francaise d'Oncologie Pediatrique LMB89 protocol: Highly effective multiagent chemotherapy tailored to the tumor burden and initial response in 561 unselected children with B-cell lymphomas and L3 leukemia. Blood 2001; 97:3370-3379.